细胞生物学
T细胞
癌症研究
细胞毒性T细胞
癌细胞
CD8型
PD-L1
免疫耐受
生物
肿瘤微环境
抗原提呈细胞
化学
免疫系统
免疫学
白细胞介素21
免疫疗法
癌症
体外
生物化学
遗传学
作者
Brian Diskin,Salma Adam,Marcelo Ferreira Cassini,Gustavo Sanchez,Miguel Liria,Berk Aykut,Chandan Buttar,Eric Li,Belen Sundberg,Ruben D. Salas,Ruonan Chen,Junjie Wang,Mirhee Kim,Mohammad Saad Farooq,Susanna Nguy,Carmine Fedele,Kwan Ho Tang,Ting Chen,Wei Wang,Mautin Hundeyin
标识
DOI:10.1038/s41590-020-0620-x
摘要
Programmed cell death protein 1 (PD-1) ligation delimits immunogenic responses in T cells. However, the consequences of programmed cell death 1 ligand 1 (PD-L1) ligation in T cells are uncertain. We found that T cell expression of PD-L1 in cancer was regulated by tumor antigen and sterile inflammatory cues. PD-L1+ T cells exerted tumor-promoting tolerance via three distinct mechanisms: (1) binding of PD-L1 induced STAT3-dependent 'back-signaling' in CD4+ T cells, which prevented activation, reduced TH1-polarization and directed TH17-differentiation. PD-L1 signaling also induced an anergic T-bet-IFN-γ- phenotype in CD8+ T cells and was equally suppressive compared to PD-1 signaling; (2) PD-L1+ T cells restrained effector T cells via the canonical PD-L1-PD-1 axis and were sufficient to accelerate tumorigenesis, even in the absence of endogenous PD-L1; (3) PD-L1+ T cells engaged PD-1+ macrophages, inducing an alternative M2-like program, which had crippling effects on adaptive antitumor immunity. Collectively, we demonstrate that PD-L1+ T cells have diverse tolerogenic effects on tumor immunity.
科研通智能强力驱动
Strongly Powered by AbleSci AI